piperaquine has been researched along with ritonavir in 2 studies
| Studies (piperaquine) | Trials (piperaquine) | Recent Studies (post-2010) (piperaquine) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 638 | 227 | 497 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | piperaquine (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW | 1 |
| Badhan, RKS; Coleman, M; Olafuyi, O | 1 |
1 trial(s) available for piperaquine and ritonavir
| Article | Year |
|---|---|
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Malaria; Male; Nevirapine; Parasitemia; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Uganda | 2014 |
1 other study(ies) available for piperaquine and ritonavir
| Article | Year |
|---|---|
The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.
Topics: Alkynes; Antimalarials; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Malaria; Models, Biological; Population Groups; Pregnancy; Quinolines; Ritonavir; Serum Albumin, Human | 2017 |